Home › Funds › ALPS ETF Trust › ALPS Medical Breakthroughs ETF
Fund family: ALPS ETF Trust · Filed by ALPS ETF Trust (CIK 1414040) · SEC series S000047823
Ticker: SBIO (C000150206)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 582 with, 0 against, 0 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 0 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as ALPS ETF Trust’s manager page (16,050 ballot items across 21 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | ALPS ETF Trust | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 76.1% | 553 | 92.2% | 13,954 |
| Backed environmental and social shareholder proposals at US companies | n/a | 0 | 9.2% | 369 |
No item-level comparison with other ALPS ETF Trust funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.
The same votes as “with management” above, by the sector of the company voted on. 83.7% of this fund’s 582 such votes could be given a sector; the other 95 (16.3%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 487 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 321 | 0 |
| Audit-related | 91 | 0 |
| Say-on-Pay | 80 | 0 |
| Compensation | 50 | 0 |
| Corporate Governance | 31 | 0 |
| Capital Structure | 18 | 0 |
| Extraordinary Transactions | 5 | 0 |
| Other Social Issues | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Edgewise Therapeutics, Inc. | June 4, 2026 | $4M | 5 | 0 |
| Oruka Therapeutics, Inc. | June 2, 2026 | $3M | 4 | 0 |
| Dianthus Therapeutics, Inc. | May 21, 2026 | $3M | 5 | 0 |
| Tarsus Pharmaceuticals, Inc. | June 25, 2026 | $3M | 6 | 0 |
| Travere Therapeutics, Inc. | May 19, 2026 | $3M | 14 | 0 |
| Viking Therapeutics, Inc. | May 19, 2026 | $3M | 4 | 0 |
| Acadia Pharmaceuticals Inc. | May 29, 2026 | $3M | 6 | 0 |
| Vericel Corporation | April 29, 2026 | $3M | 9 | 0 |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
597 ballot items at 88 meetings in 2025-2026. Download all votes (CSV)
In the 2025-2026 proxy season, ALPS Medical Breakthroughs ETF (SBIO) voted at 88 shareholder meetings of 88 companies, on 597 ballot items in all. Where management made a recommendation, the fund followed it on 100.0% of the items and voted against it 0 times. It voted FOR the board's own proposals less often than ALPS ETF Trust's funds as a whole (76.1% against 92.2%). 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of ALPS ETF Trust’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.